Randomized phase III study of nivolumab and ipilimumab versus carboplatin-based doublet in first-line treatment of PS 2 or elderly (≥ 70 years) patients with advanced non–small cell lung cancer (Energy-GFPC 06-2015 study).

医学 无容量 内科学 卡铂 培美曲塞 危险系数 肺癌 临床终点 肿瘤科 易普利姆玛 中期分析 实体瘤疗效评价标准 临床研究阶段 随机对照试验 癌症 胃肠病学 化疗 置信区间 免疫疗法 顺铂
作者
H. Léna,I. Monnet,Olivier Bylicki,Clarisse Audigier-Valette,Lionel Falchero,Alain Vergnenégre,Pierre Demontrond,Laurent Greillier,Margaux Geier,Florian Guisier,Chantal Decroisette,Chrystèle Locher,R. Corre,Claire Cropet,CHRISTOS CHOUAID,Charles Ricordel,GFPC
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (16_suppl): 9011-9011 被引量:33
标识
DOI:10.1200/jco.2022.40.16_suppl.9011
摘要

9011 Background: Combination of anti-PD1 and CTLA4 have showed superiority to chemotherapy (CT) in advanced non–small cell lung cancer (NSCLC), but data for fit elderly or PS2 patients are scarce. Methods: eNErgy compared the combination of nivolumab ipilimumab (N-I) to a platinum doublet in elderly or PS2 patients with advanced NSCLC. Primary endpoint was overall survival (OS), secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and safety. Main inclusion criteria were: stage IV histologically proven NSCLC, age ≥ 70 y, and PS 0/1/2 or age < 70 and PS2, EGFR ALK/ROS1 negative, judged fit enough to receive a platinum doublet. The main exclusion criteria were active cerebral metastasis or contraindication to N-I. Patients were randomly selected 1/1, stratified by age (≥ 70 vs. < 70 y), PS (0/1 vs. 2), and histology (squamous vs. no-squamous). Nivolumab (240 mg, 2w), ipilimumab, 1 mg/kg, 6w, was administrated until progression or unacceptable toxicity. CT was planned for 4 cycles, with carboplatin (AUC5) and pemetrexed (500 mg/m2, 3w) or paclitaxel (90 mg/m2, d1,d8, d15); 242 patients had to be randomized to detect a treatment effect hazard ratio (HR) on OS of 0.65, with a 85% power at a 2-sided alpha level of 5%. Results: A preplanned interim analysis carried out after observation of 33% of deaths, out of 174 randomized patients, showed a risk of futility especially for PS 2 patients, HR: 1.8 (95% CI, 0.99-3.3). This led to a halt in randomization but continued follow-up of the 204 patients randomized at the time of the decision. The current final analysis is carried out 18 months after the inclusion of the last patient: men, 71%, median age 74 (51-89, PS 0/1/2 in 30%, 37.5%, and 36.6% respectively), smokers or former smokers in 25.5 and 64.4%, with 62% adenocarcinoma. The median OS of N-I and chemo arms were 14.7 (95% CI, 8.0-19.7) and 9.9 (95% CI, 7.7-12.3) months, HR 0.85, 95% CI, 0.62-1.16. The subgroup analyses showed a significant benefit of the association N-I compared to CT for elderly PS 0/1 patients, with median OS of 22.6 (95% CI, 18.1-36) vs. 11.8 (95% CI, 8.9-20.5) months, p = 0.02. In PS2 patients, median OS of N-I and CT arms was 2.9 (1.4-4.8) vs. 6.1 (3.5-10.4) months (p = 0.22). Median PFS was significantly in favor of N-I arm in the entire population: 5.5 (2.8-8.7) vs. 4.6 (3.5-5.6); p = 0.015. Safety was similar with 31.4% of patients with grade ≥ 3 related SAES in N-I arm vs. 49.5% for CT. Treatment was discontinued for toxicity in 28.6% in N-I arm vs. 22.3% of patients in CT arm. Conclusions: Despite no statistically significant benefit in OS observed in the entire population, there was a clinical signal of efficacy of N-I combination over platinum doublet in elderly NSCLC patients PS 0-1 with a significant benefit of OS of 22.6 months vs. 11.8 for CT arm. Clinical trial information: NCT03351361.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李星云完成签到,获得积分10
刚刚
刚刚
HaohaoLi完成签到,获得积分10
1秒前
minkeyantong完成签到 ,获得积分10
1秒前
只只完成签到,获得积分10
1秒前
ZZU1997发布了新的文献求助10
1秒前
1秒前
YY发布了新的文献求助10
1秒前
研友_24789完成签到,获得积分10
1秒前
Janmy完成签到,获得积分10
2秒前
W10完成签到,获得积分10
2秒前
大个的应助被科研路顺遂采纳,获得10
2秒前
秋风的应助被幸福曼岚采纳,获得10
2秒前
完美萤发布了新的文献求助30
3秒前
3秒前
温婉的荷花完成签到,获得积分10
3秒前
初景发布了新的文献求助10
3秒前
夏歌蝉完成签到,获得积分10
4秒前
书写笔迹发布了新的文献求助10
4秒前
4秒前
干鞅完成签到,获得积分10
5秒前
邱燈完成签到,获得积分10
5秒前
雷卿发布了新的文献求助10
6秒前
小森林发布了新的文献求助30
6秒前
6秒前
吴阳完成签到,获得积分10
7秒前
7秒前
7秒前
7秒前
杨三多完成签到,获得积分10
7秒前
乐乐发布了新的文献求助10
7秒前
shirley完成签到,获得积分10
8秒前
8秒前
回音发布了新的文献求助50
8秒前
8秒前
kk发布了新的文献求助10
8秒前
potatoes完成签到,获得积分10
8秒前
唐萧完成签到,获得积分10
9秒前
FashionBoy的应助被MissXia采纳,获得10
9秒前
华仔的应助被宫碧空采纳,获得10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570485
关于积分的说明 21812623
捐赠科研通 7776592
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557522
邀请新用户注册赠送积分活动 2479162